Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongda Xu

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Molecular Cancer Therapeutics|August 31, 2016
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer PatientsXiao Xu, Long Mao, Wanhong Xu, et al.
Journal of Medicinal Chemistry|April 20, 2007
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IVJun Feng, Zhiyuan Zhang, Michael B Wallace, et al.
Journal of Medicinal Chemistry|December 29, 2010
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IVZhiyuan Zhang, Michael B Wallace, Jun Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
Cancer Research Communications|August 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsChristopher T Chen, Vishesh Khanna, Shivaani Kummar, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Molecular Cancer Therapeutics|August 31, 2016
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer PatientsXiao Xu, Long Mao, Wanhong Xu, et al.
Journal of Medicinal Chemistry|April 20, 2007
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IVJun Feng, Zhiyuan Zhang, Michael B Wallace, et al.
Journal of Medicinal Chemistry|December 29, 2010
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IVZhiyuan Zhang, Michael B Wallace, Jun Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
Cancer Research Communications|August 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsChristopher T Chen, Vishesh Khanna, Shivaani Kummar, et al.
Pageof 3